The power and pitfalls of IL-12.
In this issue of Blood, Pegram and colleagues describe the ability to improve adoptive T-cell therapies by engineering T cells to secrete the potent proinflammatory cytokine IL-12.1 These exciting findings significantly extend previous observations made in a murine melanoma model targeting naturally occurring tumor antigens.2,3